Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer

Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries

ASCO and WHO to collaborate on quality indicators for cancer facilities

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer

Ramucirumab plus pembrolizumab improves OS in advanced NSCLC

The role of the Global Coalition for Radiotherapy in the war in Ukraine

Youth Cancer Europe: Aiding Ukrainian refugees during the crisis

War in Ukraine: Impacts on the Slovakian cancer care system

Inspiration Family: Challenges of the Ukrainian cancer charity on the frontline

War in Ukraine: The European Cancer Organisation's response to the refugee crisis